ExpreS2ion Biotech Holding AB (EXPRS2) AI Stock Analysis

• Market Cap: kr60.48M
• Dividend Yield: N/A
• Average Volume (3M): 27.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.30
• Revenue Growth: -36.71%
• EPS Growth: 72.81%
• Country: SE
• Employees: 20
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): -4.30
• Shares Outstanding: 2,658,346
• 10 Day Avg. Volume: 42,166
• 30 Day Avg. Volume: 27,624
• PEG Ratio: -0.08
• Price to Book (P/B): 0.66
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: kr23.50 ▲(3.30%Upside)

The overall score reflects the company's financial challenges, with consistent losses and negative cash flow being the most significant factors. While there is some positive technical momentum, the lack of profitability and valuation concerns weigh heavily on the stock's outlook.

ExpreS2ion Biotech Holding AB Business Overview & Revenue Model

Company Description

ExpreS2ion Biotech Holding AB (EXPRS2) is a biotechnology company focused on the development and commercialization of innovative technologies and products within the biopharmaceutical industry. The company specializes in protein production, utilizing its proprietary ExpreS2 platform, which is based on Drosophila S2 cells for the efficient and scalable expression of recombinant proteins. ExpreS2ion Biotech serves sectors such as vaccine development, diagnostics, and therapeutic protein production, providing solutions to both research institutions and the pharmaceutical industry.

How the Company Makes Money

ExpreS2ion Biotech Holding AB generates revenue through several streams, primarily by licensing its proprietary protein expression technology, the ExpreS2 platform, to pharmaceutical companies and research organizations. This licensing can involve upfront payments, milestone payments, and royalties based on the success of the products developed using their technology. Additionally, the company offers contract research services, where they undertake specific projects for clients, which also involves service fees. Partnerships with other biotech and pharmaceutical companies further contribute to its earnings, where collaborative research and development efforts can lead to shared revenue from co-developed products. The company may also receive funding from grants or research initiatives, contributing to its financial inflow.

ExpreS2ion Biotech Holding AB Financial Statement Overview

Summary

ExpreS2ion Biotech Holding AB is facing financial challenges with consistent net losses and negative cash flow. While the company has a stable equity position and low debt levels, its inability to generate positive income and cash flow highlights operational inefficiencies and potential risks. Strategic improvements are necessary to enhance financial performance and sustainability.

Income Statement

The company has experienced a decline in total revenue from 2023 to 2024, with a significant net loss, indicating poor profitability. The gross profit margin is negative due to higher costs than revenues. While revenue growth was positive from 2022 to 2023, it declined sharply from 2023 to 2024.

Balance Sheet

The equity ratio is moderate, reflecting a balanced but somewhat leveraged position. The debt-to-equity ratio is low, indicating limited reliance on debt. However, the return on equity is negative, showing inefficiency in generating profits from equity.

Cash Flow

The company has negative free cash flow, indicating challenges in generating cash from operations after capital expenditures. The operating cash flow to net income ratio is negative, showing cash inefficiency, despite a decrease in negative free cash flow from 2023 to 2024.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.01M	7.05M	5.09M	12.23M	5.26M
	Gross Profit
-2.67M	3.40M	5.00K	4.72M	-843.00K
	EBIT
-67.69M	-105.97M	-127.61M	-48.40M	-31.20M
	EBITDA
-64.34M	-102.45M	-124.49M	-46.38M	-28.47M
	Net Income Common Stockholders
-36.41M	-91.40M	-118.61M	-43.92M	-31.71M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
81.54M	57.60M	110.97M	138.88M	106.83M
	Total Assets
104.53M	78.69M	137.36M	151.96M	118.86M
	Total Debt
360.00K	1.71M	1.85M	1.92M	2.38M
	Net Debt
-81.18M	-55.89M	-109.12M	-35.19M	-104.45M
	Total Liabilities
40.11M	13.33M	34.04M	11.61M	24.31M
	Stockholders Equity
64.42M	65.36M	103.33M	140.35M	94.55M
Cash Flow		Free Cash Flow
-34.80M	-102.90M	-100.00M	-46.36M	-19.06M
	Operating Cash Flow
-33.93M	-100.89M	-99.61M	-45.65M	-18.18M
	Investing Cash Flow
21.27M	-2.02M	105.33M	-100.92M	-1.08M
	Financing Cash Flow
34.87M	47.84M	61.46M	74.55M	123.38M

ExpreS2ion Biotech Holding AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 22.75
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EXPRS2, the sentiment is Neutral. The current price of 22.75 is above the 20-day moving average (MA) of 21.26, above the 50-day MA of 20.38, and below the 200-day MA of 26.60, indicating a neutral trend. The MACD of 0.86 indicates Negative momentum. The RSI at 55.06 is Neutral, neither overbought nor oversold. The STOCH value of 20.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:EXPRS2.

ExpreS2ion Biotech Holding AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.31B	3.29	-45.39%	2.79%	16.77%	-0.07%
COMBI	52 Neutral	kr48.51M	―	-47.01%	―	-94.12%	-25.83%
EXPRS2	46 Neutral	kr60.48M	―	-66.45%	―	-36.71%	72.81%
MODTX	42 Neutral	kr52.11M	―	-222.24%	―	―	58.36%
ONCOZ	41 Neutral	€71.33M	―	-46.84%	―	―	45.38%
SPRINT	39 Underperform	€44.11M	―	-147.64%	―	30.02%	-3985.71%
SPAGO	38 Underperform	€73.82M	―	-105.78%	―	58.72%	70.69%